A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102
- Citation:
- Ann Oncol vol 20 (6) 1074-1079
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10 CA047577, U10 CA032291, CA33601, CA11789, U10 CA077658, CA77406, CA47577, CA35113, CA32291, U10 CA086726, CA29165, CA41287, U10 CA035279, U10 CA045808, U10 CA045389, CA60138, CA45389, CA45808, CA35279, U10 CA114558, CA12046, U10 CA045418, CA86726, U10 CA077440, CA16450, CA77440, U10 CA041287, U10 CA035113, U10 CA047559, CA04326, CA08025, CA21060, CA47559, CA114558-02, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31946, CA07968
- Corr. Author:
- Authors:
- G. K. Philips S. Halabi B. L. Sanford D. Bajorin E. J. Small
- Networks:
- Study
- CALGB-90102
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- gefitinib, chemotherapy, EGFR, transitional cell carcinoma, urothelial